Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL287024 | 0.83 | KDM4E (0.55) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL5928881 | 0.83 | NFE2L2 (0.48) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| Hydrochloric Acid SCHEMBL8882233 | 0.81 | KDM4E (0.53) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL29503858 | 0.81 | PLAU (0.53) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL312146 | 0.81 | L3MBTL1 (0.60) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL2268684 | 0.81 | KDM4E (0.53) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL1101140 | 0.81 | PLAU (0.53) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| Hydrochloric Acid SCHEMBL11097642 | 0.80 | L3MBTL1 (0.58) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| SCHEMBL796222 | 0.80 | L3MBTL1 (0.46) | NFE2L2PLAUCTSAL3MBTL1NPC1 | |
| Alcohol SCHEMBL28974251 | 0.79 | KDM4E (0.50) | NFE2L2PLAUCTSAL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108864053-B | Tubulin inhibitor and application thereof in antitumor drugs | 浙江药苑生物科技有限公司 | 2020-12-01 | — | — | CN | disclosed |
| CN-108675992-B | Antineoplastic medicine acting on tubulin | 浙江药苑生物科技有限公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103221408-A | Triazine-oxadiazole compounds | NOVARTIS AG | 2013-07-24 | — | — | CN | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NFE2L2 561/4885PLAU 4448/4885CTSA 4474/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NFE2L2 561/4885PLAU 4448/4885CTSA 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.